A central focus of clinical proteomics for cancer is to identify protein biomarkers with diagnostic and therapeutic application potentials. Network-based analysis has been used in computational disease-related gene prioritization for several years. The random walk ranking (RWR) algorithm has been successfully applied to prioritizing disease-related gene candidates by exploiting global network topology in a protein-protein interaction (PPI) network. Increasing the specificity and sensitivity of biomarkers, may require on consideration of similar or closely-related disease phenotypes, and molecular pathological mechanisms shared across different disease phenotypes. In this paper, we propose a method called seed-weighted random walk ranking (SW-RWR) for prioritizing cancer biomarker candidates. This method uses the information of cancer phenotype association to assign each gene a disease-specific, weighted value to guide the RWR algorithm in a global human PPI network. In a case study of prioritizing leukemia biomarkers, SW-RWR outperformed a typical local network-based analysis in coverage, and also showed better accuracy and sensitivity than the original RWR method (global network-based analysis). Our results suggest that the tight correlation among different cancer phenotypes could play an important role in cancer biomarker discovery.
Introduction
The identification of effective biomarkers for preventive intervention or targeted therapies will increase survival rate of cancer patients dramatically (Schrohl et al., 2003) . Biomarkers are defined as measurable molecules whose presence or metabolism correlates with specific physiological and pathological process or diseases outcomes (Sawyers, 2008) . The hope for cancer protein biomarker discovery rests in the fact that cancer signaling, especially that of cancer invasiveness and metastasis, may trigger profound immunological and inflammatory responses with unique cancer molecular footprints (Saha et al., 2009) .
In recent decades, genome technologies have been used to characterize tumors at the molecular level and offer the promise of a comprehensive understanding of cancer. However, few genes, proteins or other molecules indentified as markers stand out as superior prognostic or diagnostic tools, and even fewer have been validated and approved for clinical use (Sawyers, 2008,Polanski; and Anderson, 2006) . Several factors have made the task of effective discovery of cancer biomarkers rather illusive. First, cancer involves diverse and dynamic changes of cells at genomic, epigenomic, and functional genomic levels. Currently-used methods often failed to capture the dynamic process as pathological factors disturbed the whole molecular network. Second, candidate disease genes or biomarker prediction always over-produced "disease-specific" genes, proteins which could be easily detected in a particular disease state, but neglected their ideal sensitivity and specificity in the whole diseasome. (Sawyers, 2008, Polanski; and Anderson, 2006) In recent years, characterizing diseases by observing molecular underpinnings was recommended as a new perspective for human disease classification (Loscalzo et al., 2007) . Goh et al. constructed a graphic theoretic framework to present all known human disease phenotypes and disease gene associations -the human disease network (Goh et al., 2007) . This network indicated that most human phenotypes were interrelated. Especially, the sub-network of the cancer disease category is the most connected disease category, suggesting that many cancer phenotypes share common genetic origins. Dudley et al. built a biomarker network by linking 136 disease phenotypes to 1028 detectable plasma proteins (Dudley and Butte, 2009) . In this network, more than 80% of putative protein biomarkers were linked to multiple disease conditions. Their findings illustrated the importance of considering shared molecular pathology across diseases when evaluating biomarker specificity. To find both sensitive and specific biomarkers, therefore, we should also consider related disease phenotypes and their associated genes in the disease association network.
The interactome research continues to provide abundant molecular interaction data, including many protein-protein interaction (PPI) database, such as HPRD (Mishra et al., 2006) and HAPPI (Chen et al., 2009a) . These data have led to many recent studies, using network-based computational method for disease-related gene candidate selection, that aimed to connect known disease genes with interacting molecular entities (Chen et al., 2009b , Kohler et al., 2008 , Oti et al., 2006 . In these studies, topological information about molecule interaction networks was used for predicting and prioritizing disease genes or disease biomarkers. A common assumption in these studies was that candidate disease genes might be found in close topological proximity to known disease genes in molecule interaction networks (Chen et al., 2009b , Kohler et al., 2008 , Oti et al., 2006 , Chen et al., 2006 , Xu and Li, 2006 . A seeding strategy was often used, to incorporate prior knowledge of disease genes from public databases such as OMIM (Online Mendelian Inheritance in Man) (Hamosh et al., 2005) or literature curation, and generate disease-specific context for subsequent network topological analysis. These methods usually correlated known disease genes with candidate disease genes by relating their local topological features, such as node degrees (the number of PPI connections to a node protein), closeness (average distance to disease genes) and betweenness (average neighborhood overlapping with disease genes) (Chen et al., 2006) . Recent progress has been made prioritizing genes in molecule interaction networks using PageRank (Page et al., 2001 ) and HITS (Jon, 1999) , which were inspired by algorithms to rank web pages through Web links. These methods calculate scores to measure global similarity between functionally known genes and unknown genes, outperforming local topological association methods (Kohler et al., 2008) . For example, Sebastian et al. used a random walk (RW) algorithm to rank candidate genes within known members of a disease-gene family (Kohler et al., 2008) . Wu et al. introduced ant colony optimization (ACO) algorithm for ranking yeast PPI networks annotated with lethality information, which revealed intriguing patterns (Wu et al.) . Jing Chen et al. compared PageRank, HITS with Priors, and K step Markov methods to estimate the relative importance of candidate disease genes in PPI networks to known disease genes (Chen et al., 2009b) , which found that the three methods and their modifications yielded similar results. Huang et al. evaluated how the quality of seed genes and PPI data affect the ranking results, and suggested that disease specific prior knowledge should be included in prioritizing candidate disease genes whenever possible (Huang et al.) .
Disease biomarker selection may be based on disease gene selection that takes into account large functional molecular association networks. Suppose that a specific cancer not only suffers from the disturbance of its local sub-network, but also shares some common genetic origin with other related cancers. If so, the deregulated expression of certain functionally unknown genes/proteins on this specific cancer phenotype could be reasoned and deducted. These genes/ proteins might have potential to become cancer biomarker candidates. Beginning with the original random walk ranking (RWR) algorithm in (Kohler et al., 2008) , we propose in this paper a improved method, seedweighted random walk ranking (SW-RWR) for prioritizing candidate cancer biomarkers. In this method, we use cancer phenotype associations to assign a weighted score to each seed gene in order to guide RWR algorithm in a global human PPI network. Through a case study in leukemia, we show that SW-RWR outperformed local network-based methods. The SW-RWR method also has better accuracy and sensitivity than the original RWR (and can be seen as an example of a typical global network-based method), which incorporated information from only one disease phenotype at a time. The results suggest that the tight correlation among cancer phenotypes is very helpful in cancer biomarker discovery.
Methods
The general idea of the method used in this study is illustrated in Fig.1 . We first built a cancer phenotype association network using similarity scores between different forms of cancer, defined by the overlap of their candidate protein biomarkers. Then we retrieved the most related cancer diseases to a specific cancer from this network by their similarity scores. We assigned the specific cancer genes higher weights, while assigning related cancer genes lower weights, which were calculated according to their association with lung cancer. Finally we used these weighted seed genes to guide the RWR algorithm to prioritize all the proteins in a global human PPI network. The details of how to generate the leukemia-specific seed genes and leukemia-related seed genes, how to assign prior weights and how to calculate the ranking score of candidate biomarkers are described below.
Finding cancer disease context
The cancer candidate protein biomarkers list was obtained from Polanski M et al. (Polanski; and Anderson, 2006) who compiled it from literature review, and is believed to include genes/ proteins differentially expressed in human cancer. This list included 1261 human proteins which we mapped to 1049 distinct Uniprot IDs and 1055 distinct Entrez Gene IDs. In this study, we first classified the biomarkers into 52 types of cancer. Cancer annotation data were obtained from several sources. We included a list of 98 cancer IDs and associated cancer names contained in a paper by Goh et al. (Goh et al., 2007) .
We used the MeSH (Medical Subject Headings) database (http://www.nlm.nih.gov/mesh/) and categorized each of the 98 cancers by mapping their names to corresponding MeSH term hierarchy. We further used the GeneRif (http://www.ncbi.nlm.nih.gov/projects/GeneRIF/) database to classify the 1055 cancer candidate biomarker genes into one of the MeSH cancer categories, if the gene's GeneRif record contains functional descriptions that could be matched to a cancer MeSH term category. Then we curated the result and merged the reduplicated ones and finally got 762 putative biomarkers for 52 cancer types. Of these, there are 238 leukemia biomarkers, and these 238 proteins were considered as an "experiential biomarkers" set in this study.
Cancer phenotypes association network
We built a cancer phenotypes association network (CPAN) by identifying nodes as cancer disease phenotypes. If two phenotypes shared more than one experiential biomarker, there was an edge connecting these two nodes. We used a similarity score Sij to define the similarity between two cancer phenotypes as the following:
where Di and Dj refer to cancer related experiential biomarkers for cancer phenotype i and cancer phenotype j. We then ranked the leukemia neighbors' cancer phenotypes by similarity score values.
Random walking in PPI network for biomarkers ranking
Cancer disease genes were obtained from the OMIM morbid map (Hamosh et al., 2005) . We retrieved cancer related disease genes by using key words for particular cancers in MeSH. Human protein-protein interaction (PPI) data were retrieved from the HPRD database (Mishra et al., 2006) . In the latest release 7 there are 9462 distinct genes and 38,167 interaction pairs and all PPI information was manually extracted from the literature by expert biologists at HPRD.
We named our method "seed-weighted random walk ranking (SW-RWR)". Let G = (V, E) be the graph representing PPI network, where V is the set of nodes (proteins) and E is the set of undirected edges. Intuitively, the Random Walk (RW) method (Can et al., 2005 ) mimics a walker who starts on a source node. At every time step, the walker choose randomly among the available edges or goes back to the source node with probability c.
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where A is the normalized adjacency matrix of G, while Pt is the probability vector that the walker stays in node v at time step t. Here c is the restart probability, we chose c = 0.7. We constructed the initial probability vector P0 using the knowledge of leukemia related disease genes. Assuming that the number of leukemia disease genes is n and the total number of the top 5 related cancers' disease genes is m. We identified the prior probability of leukemia disease gene as 1/(n+0.8m) and the prior probability of other related disease genes is 0.8/(n+0.8m). So the ratio of leukemia disease genes to other related disease genes is 5:4. And the sum of all the elements in P0 vectors is 1. Candidate biomarkers ranking were then based on the values in the steady-state probability vector Pt, when 
Other methods
First, we compared with the Edge-weighted Promiscuous Hub subtraction (EPHS) strategy developed in (Chen et al., 2006) . EPHS is a local degree strategy adapted by penalizing the impact of low-quality promiscuous protein hubs on ranks. Since HPRD is a well-known high-quality PPI database, EPHS can be considered as a method that only calculates the node degrees of the first expanding disease specific networks.
Next, we compared RWR only using leukemia genes as guiding information for ranking biomarkers for comparison. As we mentioned in Introduction, the most sophisticated network-based prioritization method was RWR, random walking with restart, proposed by Kohler et al. (Kohler et al., 2008) They had used this method to rank candidate disease related genes to known members of a disease-gene family. Here, we compared our method to RWR with the same restart probability, c = 0.7.
Candidate biomarkers assessment
To evaluate our ranking methods' effect, we chose the 238 biomarkers taken from Polanski M et al. curated data (Polanski; and Anderson, 2006) as gold standard positive set (GSP). (Details in Method 2.1) As far as we know, this is the only curated comprehensive collection of candidate cancer biomarkers to date.
The following measurements are calculated to evaluate the performance of each method: (1) Coverage, calculated as the total number of biomarkers' including in the whole discovery space; (2) Sensitivity, calculated as the percent of correctly identified biomarker proteins |TOPM∩GSP|/|TOP200∩GSP|; (3) Positive Predictive Value (PPV), calculated as the probability of correct positive predictions |TOPM∩GSP|/|TOPM|.
Results

Leukemia centered disease phenotypes association network
At first, we built a cancer phenotypes association network, including 52 nodes. Each node represented a kind of cancer phenotype, and if two phenotypes shared at least one experiential biomarker, we created an association connecting them. This network included 52 cancer phenotypes, 762 experiential biomarkers and 820 associations. So on average, every two phenotypes shared more than 9 biomarkers, and one biomarker was included in 14 cancer phenotypes. All these 52 nodes integrated one connected network and most of the cancer phenotypes are tightly related to each other. For example, leukemia is connected to 44 cancer phenotypes. Then, we calculated the similarity scores between leukemia and all the other cancer phenotypes. The top 10 cancers ranked by similarity scores are shown in Table 1 . We chose top 5 cancers here for further computational model building.
To verify whether leukemia and these top 5 cancers are related to similar local network disturbance in the PPI network, we retrieved the diseases-specific local network (which can also be seen as an enrichment process). We first used disease genes in OMIM as seed genes, and then expanded them to their first PPI neighbors (Fig.2_A ) and second PPI neighbors (Fig.2_B) . Fig.2_A is the PPI network of leukemia and the top 5 cancers' disease genes. Fig.2_B is the PPI network of leukemia, including the top 5 cancers' disease genes and the genes connecting these disease genes by PPI. From Fig.2 , we can see that the cancer disease phenotypes tightly related to each other. Our analysis supported the hypothesis that cancer was a kind of disease suffering from local network disturbance. One gene may have high probability to be important in another type of cancer, if its deregulation was verified to play an important role in one type of cancer. Those networks were visualized and drawn via ProteoLens (Huan et al., 2008) .
Biomarker coverage comparison of various sub-network constructing method
We calculated the distribution of biomarkers that surrounds the known disease genes. The sub-network was expanded by the nearest neighbor expandison (NNE) method (Chen et al., 2006) . We also calculated the coverage of potential leukemia biomarkers, listed in Table 2 and Table 3 . Fig. 3 is the Venn diagram of the overlap among the genes in leukemia disease gene expansion network, the genes in the top 5 related disease genes expansion network and the experiential leukemia biomarker set. As seen in Table 2 and Fig.3 , the first neighbors of leukemia disease genes have lower coverage, including 78 experiential biomarkers 33.05%. The second expansion increased coverage to 80.7%, but the total protein number increased sharply, which indicates that too much irrelevant information was included.
Interestingly, from Table 3 , we see that most of the leukemia biomarkers which were first or second PPI partners of the top 5 disease genes, always belong to the second expansion network of leukemia genes (92/95 in first expansion and 192/208 in second expansion). It meant if we confine the discover space between the leukemia disease genes' second expansion and the top 5 disease genes first expanding proteins set, we find 76.4% biomarkers of the all leukemia disease genes' second expanding network and 96.8% biomarkers of all the top 5 cancer disease-gene first expanding protein set. From this analysis, we can also see that the related cancer phenotypes are of assistance in predicting candidate biomarkers' for leukemia. The global methods for prioritizing biomarkers such as RWR, which took advantage of all the PPIs is necessary for better coverage. Typical local distance methods only use first expansion information, such as EPHS, whose best coverage is only 33.05%. In this way, a lot of important information is missed.
Assessment of leukemia candidate protein biomarkers' ranking results
We compared the sensitivity and accuracy (evaluated by PPV) performance between our SW-RWR method and the original RWR method. Both of them are global networkbased analyes using all the HPRD proteins, so they are believed to have ideal coverage. The improvement of SW-RWR is to add the cancer phenotype association information for guiding the RW in the global PPI network for ranking candidate biomarkers. Fig.4_A shows a comparison of their sensitivity performances distributed over the top 200 predicted biomarkers. The SW-RWR significantly outperformed RWR greatly, about 10% to 20%. Fig.4_B shows the distribution of the PPV performances comparisons distribution, SW-RWR outperformed RWR again.
The top 20 candidate protein biomarkers selected by SW-RWR are shown in Table 4 . The top 20 candidate biomarkers included 13 seed disease genes and 7 experiential biomarkers. As indicated in references (Doubek et al., 2009 , Lee S et al., 2009 , Mao et al., 2008 , Yagasaki et al., 1999 , the biomarker candidates discovered by SW-RWR, such as MLH1, ACSL6, MYC, CBFB et al. were newly implicated to play important roles in leukemia disease.
Conclusions and Discussion
Biomarkers are chosen to include the significant molecules reflecting the pathological states, but it is hard to find such molecules indicating different cancer phenotypes. Cancer phenotypes share common genetic origins (Goh et al., 2007) . Although there are already more than 200 cancer genes with detailed descriptions in OMIM today, many molecular processes related to specific cancer phenotypes remain unknown.
In this research, we built a new computational model for predicting cancer protein biomarkers. The main idea of our method is to consider the position of genes in the disease phenotypes within the whole cancer diseasome to guide the candidate biomarkers prioritization in human PPI network. We used the leukemia biomarker candidate prioritizing as a case study here. First, we classified 1261 potential cancer candidate biomarkers into 52 individual cancer phenotypes using MeSH terms and text mining techniques. Second, we built a cancer phenotypes associated network (CPAN), in which the nodes indicated cancer phenotypes and edges indicated the common experiential biomarkers shared by these two phenotypes. Third, we extracted the leukemia disease context in the CPAN and assigned each gene node in the human PPI network a prior score after evaluating the genes correlation with leukemia. Fourth, we used SW-RWR to prioritize the candidate protein biomarkers for leukemia. Compared with the widely-used candidate disease gene ranking method, i.e. RWR method, SW-RWR showed better performance as discovering the candidate biomarkers in accuracy and sensitivity.
In the top 20 genes we listed in table 4, although MLH1, ACSL6, MYC, and CBFB have not been collected by OMIM or experiential biomarkers, these genes/proteins are all highly ranked by our SW-RWR method. Some newly published references stated that they might have important relationships with leukemia. The MLH1 3'-untranslated region (3'-UTR) leads to DNA mismatch repair deficiency and conferred leukemia relapse, likely by down-regulating MLH1 expression at the mRNA level (Mao et al., 2008) . The fusion of the ETV6 gene to ACSL6 has been identified in acute myelogenous leukemia (Yagasaki et al., 1999) . MYC amplification in acute myeloid leukemia patients marks the state of the chemotherapy response (Lee S et al., 2009) . The fusion gene type of CBFB is always related to leukemia (Doubek et al., 2009 ). Based on the common origins of most of cancers, the results suggest that the tight correlation among different cancer phenotypes could provide useful as an additional supervision in cancer biomarker discovery. 
